HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age65-85
SponsorGöteborg University

About this trial

It is not difficult to imagine that leaking urine affects life in many contexts. Unfortunately, it is everyday life for far too many people in our society. According to the National Board of Health and Welfare, incontinence primarily affects older people, and both women and men are vulnerable. In Sweden, just over 530,000 people over the age of 65 have problems and almost 80 percent of all people in special housing have such urine leakage that they need to use incontinence aids. First-line treatment for women with incontinence is local estrogen and pelvic floor training. Surgery may also be considered if this treatment does not provide sufficient effect.

A new type of treatment for stress, urge and mixed incontinence is now on the market, High-Intensity Focused Electromagnetic (HIFEM®) treatment. This involves electromagnetic stimulation that causes contractions in the pelvic floor muscles. The treatment is not painful or invasive and the patient sits clothed in the treatment chair. In Sweden, HIFEM® is mainly available outside of traditional healthcare and is very expensive. It is also often given by unauthorized actors.

We are now planning a study whose purpose is to evaluate the effect of HIFEM® on women over 65 years of age with stress incontinence. A group of 100 women will be randomized to:

1. Standard treatment, i.e. physiotherapy-led pelvic floor training 2. As above with the addition of 10 treatments of 30 minutes with HIFEM®.

The evaluation will be carried out regarding leakage, need for incontinence aids and pelvic floor strength immediately and six months after the intervention. The women will also rate their incontinence symptoms, physical activity level, physical function and quality of life. A group will also be interviewed about their experiences of living with incontinence and the treatment. Before the study start, a case study will be performed in which 10 women will be included. They will receive 10 treatments and measure, with the same outcomes, the effects.

Alternative treatment methods are important to meet the care needs we have today but also in the future. If treatment with HIFEM® can be effective for women over 65, it could, in addition to reducing incontinence problems and the consequences of these problems, also lead to reduced costs for society regarding care and incontinence products, as well as reduced environmental impact.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women aged 65-85 ears

Having daily stress incontinence requiring use of incontinence aids.

Living in ordinary housing without home (health-) care

Being physically active and can move independently both indoors and outdoors.

Disqualifiers

-Ongoing coached pelvic floor training

Heart disease where treatment is contraindicated

Lung disease with chronic cough

Pacemaker, defibrillator, neurostimulator, medication pump, and implanted devices in the head or spinal cord

Trial design

Design model

Parallel

Treatments tested in this trial

  • Pelvic floor training as described in point a above, with the addition of HIFEM.

    Device

    Pelvic floor training with the addition of HIFEM. The treatment will be administered over 8-10 sessions of 30 minutes each, over a period of 4-6 weeks, with two sessions per week. During treatment, the women will sit fully clothed in a treatment chair and receive standardized stimulation of the pelvic floor muscles.

  • Pelvic Floor exercises

    Other intervention

    Pelvic floor training according to national guidelines

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Arm A - Standard Pelvic Floor TrainingActive comparator 1 intervention
Group B: Arm B - Pelvic Floor Training + HIFEMExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Leakage volume

Weight of leakage

Time frame
From enrollment to the end of treatment at 5 weeks. Follow up at 6 months and at 1 year.
2

Urinary incontinence severity

International Consultation on Incontinence Questionnaire-short form (ICIQ-SF). Scale from 0 (no symptoms) to 21 (maximal symptoms).

Time frame
Baseline, post-treatment, 6 months, 12 months

Secondary outcomes

1

Number of leakage/day

Number/ day

Time frame
From enrollment to the end of treatment at 5 weeks. Follow up at 6 months and at 1 year.
2

Need of continence aids

Number of aids used per day

Time frame
From enrollment to the end of treatment at 5 weeks. Follow up at 6 months and at 1 year.
3

Pelvic floor muscle strength

Modified Oxford Scale, pre- and post-treatment, by a blinded assessor. Scale from 0 (no contraction) to 5 (very strong muscle contraction).

Time frame
Before and after the intervention
4

Impact of urinary incontinence on sexual health

The questionnaire "Impact of urinary incontinence on sexual health (ICIQ-FLUTSsex). Total score from 0 (no reported symtoms) to 14 (severe symtoms).

Time frame
At baseline, post-treatment, 6 months, and 12 months.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: